
Tactile Systems (TCMD) Stock Forecast & Price Target
Tactile Systems (TCMD) Analyst Ratings
Bulls say
Tactile Systems Tech is supported by a durable lymphedema franchise that grew about 12% to 13% year over year across 2Q26 and 3Q26, reflecting stronger order volumes, broader commercial reach, and improving access to advanced pump therapy under Medicare policy changes. Its 3Q26 revenue of $91.9M and adjusted EPS of $0.31 beat expectations, while gross margin ran about 150 bps ahead of consensus and adjusted EBITDA guidance was raised to $50M-$52M, signaling steadily improving profitability. The company also has multiple growth drivers ahead, including new product cycles like Flexitouch Pro, MyoSleeve, and LymphaTech, plus a stable Airway Clearance business and a valuation that remains below peers.
Bears say
Tactile Systems Tech is facing a negative fundamental setup because its Airway Clearance business fell 25.1% year over year to $10.0M, with management blaming prolonged excess AffloVest inventory at DME providers rather than a clean demand recovery. Although FY26 revenue guidance of $360M-$366M and adjusted EBITDA of about $49M-$52M imply growth, the outlook is increasingly dependent on Lymphedema while Airway Clearance remains muted, limiting diversification and leaving results vulnerable to channel timing issues. Margin pressure and execution risk also remain concerns, as gross margin guidance slipped to roughly 76%-76.5% while OpEx is still expected to rise 10%-12% year over year amid slower commercial uptake, sales force inefficiencies, and competition.
This aggregate rating is based on analysts' research of Tactile Systems and is not a guaranteed prediction by Public.com or investment advice.
Tactile Systems (TCMD) Analyst Forecast & Price Prediction
Start investing in Tactile Systems (TCMD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Tactile Systems (TCMD) Forecast
Tactile Systems (TCMD) Analyst Forecast & Price Prediction
Start investing in Tactile Systems (TCMD)
Order type
Buy in
Order amount
Est. shares
0 shares